The STRIDE regimen, involving dual blockade of PD-L1 and CTLA-4, significantly enhanced antitumor immunity, as evidenced by extensive tumor necrosis and lymphoplasmacytic infiltration. The gene discussed is CD274; the disease is neoplasm.